Importantly, in the current study, we showed for the first time that the prognosis of u-HCC patients treated with Atezo/Bev therapy was clearly stratified based on TERT ctDNA mutation and AFP level (Figure 5), suggesting the usefulness of ctDNA profiling as a prognostic biomarker for these patients. This evidence concerns the gene TERT and hepatocellular carcinoma.